Short Interest in Inventiva S.A. (NASDAQ:IVA) Expands By 34.9%

Inventiva S.A. (NASDAQ:IVA) was the target of a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 77,700 shares, an increase of 34.9% from the March 31st total of 57,600 shares. Based on an average daily volume of 39,500 shares, the days-to-cover ratio is presently 2.0 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Inventiva stock. Commonwealth Equity Services LLC boosted its stake in shares of Inventiva S.A. (NASDAQ:IVA) by 20.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,435 shares of the company’s stock after purchasing an additional 4,155 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Inventiva were worth $103,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Stock Performance

NASDAQ:IVA traded down $0.06 on Tuesday, reaching $3.18. The stock had a trading volume of 2,102 shares, compared to its average volume of 34,210. Inventiva has a 12-month low of $2.43 and a 12-month high of $5.05. The company has a 50-day moving average of $3.63 and a 200 day moving average of $3.89.

Wall Street Analyst Weigh In

IVA has been the topic of several research analyst reports. Canaccord Genuity Group lifted their price target on Inventiva from $12.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, April 8th. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Inventiva in a research report on Monday, April 1st. Stifel Nicolaus reduced their target price on shares of Inventiva from $27.00 to $25.00 and set a “buy” rating for the company in a report on Friday, February 16th. Finally, Lifesci Capital reiterated an “outperform” rating on shares of Inventiva in a research report on Friday, January 5th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $17.00.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.